InduPro Raises $77M Series B as IDP-001 Enters Phase 1

InduPro closed a $77M Series B led by The Column Group on August 12, 2026. The financing arrived with a more important operating milestone: the company said it dosed the first patient in the Phase 1 study of IDP-001, its lead oncology program.

The round gives InduPro capital to support Phase 1 development, generate early proof-of-concept data for IDP-001, and advance its preclinical pipeline. It also moves the company into the part of biotechnology where an elegant platform has to answer harder questions about safety, tolerability, pharmacokinetics, and preliminary antitumor activity in people.

What Happened

The Column Group led InduPro's Series B. Existing investors Vida Ventures, MRL Ventures Fund, Emerson Collective advised by Yosemite, and Euclidean Capital participated alongside new investors Solasta Ventures, Sanofi, and Eli Lilly and Company. The syndicate combines specialist life-science funds with pharma companies that already understand the partnering value of InduPro's proximity-guided platform.

InduPro previously announced an $85M Series A in June 2024. Its two disclosed priced rounds total $162M, although that figure does not include undisclosed strategic equity investments associated with earlier Sanofi and Lilly collaborations. The company did not disclose a valuation or individual check sizes for the Series B.

The financing and clinical milestone appeared together in InduPro's official announcement. The pairing is important because capital is most useful when it buys a defined experiment, and InduPro has now identified the experiment that will shape its next chapter.

How IDP-001 Works

IDP-001 is an investigational bispecific antibody-drug conjugate targeting EGFR and TAPA-E1, a novel Tumor-Associated Proximity Antigen. EGFR is a familiar oncology target found across many solid tumors, but its presence on healthy tissue can constrain how aggressively therapies can target it. InduPro's approach is designed to add another layer of selectivity by focusing on proteins that repeatedly appear close together on the surface of cancer cells.

The company's platform maps those cell-surface protein neighborhoods and uses the spatial relationships to identify co-target pairs. IDP-001 combines EGFR with TAPA-E1 in an effort to improve tumor selectivity, internalization, antitumor activity, and tolerability. Those are design goals and development hypotheses, not established clinical benefits, which is exactly why the trial matters.

The registered study, NCT07602842, is an open-label Phase 1/2 protocol evaluating IDP-001 in adults with advanced or metastatic squamous and non-squamous non-small cell lung cancer and other squamous solid tumors. The current Phase 1 work evaluates safety, tolerability, pharmacokinetics, and preliminary antitumor activity. InduPro has now reported that the first patient has been dosed.

Why This Matters

Biotech platforms are often financed on the promise that one discovery engine can generate many programs. The strategic value appears only when the engine produces candidates, attracts credible partners, and advances a program into the clinic without becoming a permanent research project. InduPro has now crossed that operational line with IDP-001.

The first clinical program is especially consequential because proximity-guided targeting is meant to solve a familiar precision-oncology problem. A target can be biologically relevant and still be difficult to drug selectively if it also appears on healthy cells. By using the relationship between EGFR and TAPA-E1, InduPro is testing whether spatial context can help distinguish disease tissue more effectively than target expression alone.

That could matter for squamous cancers, where actionable driver mutations and established antibody-drug conjugate targets have not delivered the same breadth of precision treatment seen in some other solid tumors. A favorable Phase 1 signal would not validate the entire platform, but it could provide the first human evidence that InduPro's target-pairing logic deserves broader clinical investment.

The Investor Signal

The Column Group's decision to lead again gives the round continuity with InduPro's Series A. Vida Ventures, MRL Ventures Fund, Emerson Collective, and Euclidean Capital also returned, while Solasta Ventures, Sanofi, and Lilly expanded the syndicate. Follow-on participation is not proof of clinical success, but it indicates that investors with access to the company's progress were willing to finance the transition into human testing.

Sanofi and Lilly add another layer of context because both companies entered strategic relationships with InduPro before joining the Series B. Their participation suggests interest in the platform's ability to support internal pipeline development and partnered programs across oncology and autoimmune disease. Pharma involvement does not guarantee an outcome, but InduPro has built multiple paths for its discovery engine to create value.

CEO Prakash Raman, Ph.D., leads the company alongside President and CSO Scott Lesley, Ph.D., and CMO Amanda J. Redig, M.D., Ph.D. Scientific Founder K. Chris Garcia, Ph.D., anchors the company's scientific origin, while the broader founding team includes researchers who helped develop its protein-proximity mapping approach. InduPro does not identify a current CTO.

What Comes Next

The Series B proceeds are expected to support Phase 1 development and early proof-of-concept work for IDP-001 while moving the broader preclinical pipeline forward. Near-term attention should stay on trial execution, safety, dosing, pharmacokinetics, and whether preliminary activity supports the company's tumor-selectivity thesis. These are the measurements that can turn a platform story into a clinical one.

For operators and investors, InduPro offers a clean example of platform leverage. The company has used one discovery framework to generate internal programs, attract strategic collaborations, and bring a lead asset into human testing. The $77M Series B extends the runway, but the durable value will come from whether proximity-guided target selection produces medicines with a meaningful therapeutic window.

That makes this round less about celebrating a capital total and more about funding a sharper question. InduPro has raised $162M across its disclosed Series A and Series B rounds, assembled a sophisticated investor group, and placed IDP-001 in the clinic. The next evidence will come from patients, and that is where the proximity thesis finally has to prove how close it is to becoming a medicine.